natgillin/translations-raw huggingface dataset:
Oral solution 50 mL oral solution 150 mL oral solution 480 mL oral solution
Peroralna raztopina 50 ml peroralne raztopine 150 ml peroralne raztopine 480 ml peroralne raztopine
What ABILIFY is and what it is used for What you need to know before you take ABILIFY How to take ABILIFY
Kaj je zdravilo ABILIFY in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo ABILIFY Kako jemati zdravilo ABILIFY
Intramuscular use.
intramuskularna uporaba
The oral solution contains fructose and sucrose.
Peroralna raztopina vsebuje fruktozo in saharozo.
Description of selected adverse reactions
Opis izbranih neželenih učinkov Odrasli
• sudden unexplained death,
• nenadna nepojasnjena smrt, • nepravilno bitje srca, ki lahko ogrozi življenje,
Irritability associated with autistic disorder in paediatric patients (see section 4.2) Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2 mg/day to 15 mg/day) and one fixed-dose (5 mg/day, 10 mg/day, or 15 mg/day)] and in one 52-week open-label trial.
Uporabo aripiprazola so pri bolnikih, starih od 6 do 17 let, raziskovali v dveh 8-tedenskih, s placebom nadzorovanih preskušanjih [v enem z uporabo fleksibilnega odmerka (od 2 mg/dan do 15 mg/dan), v drugem pa z uporabo fiksnega odmerka (5 mg/dan, 10 mg/dan ali 15 mg/dan)] in v enem 52tedenskem odprtem preskušanju.
Oral solution Clear, colourless to light yellow liquid solution.
Bistra, brezbarvna do rumenkasta tekočina.
• accidental inhalation of food with risk of pneumonia (lung infection),
• naključno vdihanje hrane s tveganjem za pljučnico (okužba pljuč), • krči mišic v grlu,
A second injection may be administered 2 hours after the first injection, on the basis of individual clinical status and no more than three injections should be given in any 24-hour period.
Na osnovi individualnega kliničnega statusa lahko bolnik prejme drugo injekcijo 2 uri po prvi.
Microcrystalline cellulose Hydroxypropyl cellulose Magnesium stearate
Jedro tablete laktoza monohidrat koruzni škrob mikrokristalna celuloza hidroksipropilceluloza magnezijev stearat
Schizophrenia in adolescents aged 15 years and older In a short-term placebo-controlled clinical trial involving 302 adolescents (13 to 17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):
V kratkotrajnem, s placebom nadzorovanem kliničnem preskušanju, ki je vključevalo 302 mladostnika (13 do 17 let) s shizofrenijo, so bili neželeni učinki po pogostnosti in vrsti podobni kot pri odraslih, z izjemo naslednjih neželenih učinkov, ki so bili pri mladostnikih, ki so prejemali aripiprazol, pogostejši kot pri odraslih, ki so prejemali aripiprazol (in pogostejši kot pri placebu):
This medicine can be given regardless of meals.
Zdravilo ABILIFY se lahko daje ne glede na obroke.
• uncontrollable twitching, jerking or writhing movements, restless legs,
• neobvladljivo trzanje, krčeviti gibi, nemirne noge,
ABILIFY 5 mg tablets Indigo carmine aluminium lake (E 132)
ABILIFY 5 mg tablete indigotin (E 132)
Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (greater than 1 in 100 patients).
Neželeni učinki pri mladostnikih, starih 13 let in starejših, so bili po pogostnosti in vrsti podobni neželenim učinkom pri odraslih, z izjemo naslednjih: zaspanost, nenadzorovani trzaji ali nehotni gibi, nemirnost in utrujenost, ki so bili zelo pogosti (prisotni pri več kot 1 od 10 bolnikov), ter bolečina v zgornjem predelu trebuha, suha usta, hiter srčni utrip, povečanje telesne mase, povečan apetit, trzanje mišic, nenadzorovano gibanje udov in omotica, še posebej pri vstajanju iz ležečega ali sedečega položaja, ki so bili pogosti (prisotni pri več kot 1 od 100 bolnikov).
If you forget to take ABILIFY
Če ste pozabili vzeti zdravilo ABILIFY
These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 mg/kg/day to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose).
104 tednih odmerjanja od 20 mg/kg/dan do 60 mg/kg/dan (od 3- do 10-kratna srednja AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka) ter zvečana pogostnost adrenokortikalnih karcinomov in kombiniranih adrenokortikalnih adenomov/karcinomov pri podganjih samicah ob odmerjanju 60 mg/kg/dan (10-kratna srednja AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka).
What you need to know before you take ABILIFY Do not take ABILIFY
Kaj morate vedeti, preden boste vzeli zdravilo ABILIFY Ne jemljite zdravila ABILIFY
ABILIFY solution for injection is for intramuscular use.
Raztopina za injiciranje zdravila ABILIFY je namenjena za intramuskularno uporabo.
If you are taking ABILIFY, your doctor will discuss with you whether you should breast-feed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding.
Če prejemate zdravilo ABILIFY, vam bo zdravnik pomagal pri odločitvi glede dojenja z upoštevanjem prednosti dojenja za otroka in prednosti zdravljenja za vas.
ABILIFY contains fructose and sucrose
Zdravilo ABILIFY vsebuje fruktozo in saharozo
Red iron oxide (E 172)
rdeči železov oksid (E 172)
Patients who have been given too much aripiprazole have experienced the following symptoms:
Bolniki, ki so prejeli večji odmerek aripiprazola, kot bi smeli, so imeli naslednje simptome:
Before treatment with ABILIFY, tell your doctor if you suffer from
Pred začetkom zdravljenja z zdravilom ABILIFY morate obvestiti zdravnika, če:
ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day (i.e. 10 mL to 30 mL solution/day).
Zdravilo ABILIFY je učinkovito v razponu odmerkov od 10 mg/dan do 30 mg/dan (tj. od
The recommended initial dose for ABILIFY solution for injection is 9.75 mg (1.3 mL), administered as a single intramuscular injection.
Priporočeni začetni odmerek zdravilom ABILIFY raztopina za injiciranje je 9,75 mg (1,3 ml).
Aripiprazole doses ranging from 0.5 mg to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.
S pozitronsko emisijsko tomografijo so pokazali, da je 2-tedenska uporaba odmerkov od 0,5 mg do 30 mg aripiprazola enkrat na dan pri zdravih preiskovancih povzročila od odmerka odvisno zmanjšanje vezave 11C-rakloprida, liganda receptorjev D2/D3, v nucleusu caudatusu in putamnu.
• The other ingredients are lactose monohydrate, maize starch, microcrystalline cellulose, hydroxypropylcellulose and magnesium stearate.
• Druge sestavine zdravila so laktoza monohidrat, koruzni škrob, mikrokristalna celuloza, hidroksipropilceluloza, magnezijev stearat.
• The other ingredients are sulfobutylether β-cyclodextrin (SBECD), tartaric acid, sodium hydroxide, and water for injections.
• Druge sestavine zdravila so sulfobutileter betaciklodekstrin (SBECD), vinska kislina, natrijev hidroksid in voda za injekcije.
If you stop taking ABILIFY
Če prenehate jemati zdravilo ABILIFY
The efficacy of aripiprazole in paediatric subjects with Tourette's syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study conducted in SouthKorea.
n = 29) je bila ocenjena tudi s prilagodljivim odmerkom v razponu od 2 mg/dan do 20 mg/dan in začetnim odmerkom 2 mg v 10-tedenski randomizirani, dvojno slepi, s placebom nadzorovani študiji, izvedeni v Južni Koreji.
In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and 57 % in placebo.
V 26-tedenskem, s placebom nadzorovanem preskušanju stabiliziranih odraslih bolnikov s kronično shizofrenijo je peroralni aripiprazol značilno bolj zmanjšal delež recidivov: v skupini, ki je dobivala aripiprazol peroralno, jih je bilo 34 %, v tisti, ki je dobivala placebo, pa 57 %.
These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with ABILIFY, you should see your doctor.
Če opazite kakršen koli neobičajen simptom ob jemanju katerega od teh zdravil skupaj z zdravilom ABILIFY, obiščite zdravnika.
Yellow iron oxide (E 172)
rumeni železov oksid (E 172)
In the pooled trials, the incidence of low serum prolactin levels in females (< 3 ng/mL) and males (< 2 ng/mL) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively.
Podatki združenih preskušanj kažejo, da je bila pri zdravljenju z aripiprazolom pogostnost nizkih vrednosti prolaktina v serumu pri deklicah (< 3 ng/ml) 58,7 % (27/46), pri dečkih (< 2 ng/ml) pa 86,6 % (258/298).
Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours.
kompulzivno nakupovanje, kompulzivno prenajedanje in drugo impulzivno in kompulzivno vedenje.
• abnormal muscle breakdown which can lead to kidney problems,
• nenormalna razgradnja mišic, ki lahko povzroči težave z ledvicami, • bolečine v mišicah,
Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).
Preobčutljivost Tudi pri aripiprazolu se lahko pojavijo preobčutljivostne reakcije v obliki simptomov alergije (glejte poglavje 4.8).
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Predklinični podatki o varnosti na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala, vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
However, the clinical relevance of this finding has not been established.
vendar ta učinek ne velja za klinično pomembnega.
However, the oral solution should not be diluted with other liquids or mixed with any food prior to administration.
Vendar peroralne raztopine pred zaužitjem ne smete redčiti z drugimi tekočinami ali mešati s hrano.
Non-clinical data reveal no special hazard for humans based on conventional oral aripiprazole studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Predklinični podatki o varnosti peroralnega aripiprazola na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala, vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
However, in a single-dose, intramuscular study of aripiprazole (dose 15 mg) in healthy subjects, administered simultaneously with intramuscular lorazepam (dose 2 mg), the intensity of sedation was greater with the combination as compared to that observed with aripiprazole alone.
Vendar pa je v študiji pri zdravih osebah, ki so prejele enkratni intramuskularni odmerek aripiprazola (15 mg) skupaj z enkratnim intramuskularnim odmerkom lorazepama (2 mg), bila stopnja sedacije pri uporabi kombinacije večja kot pri uporabi aripiprazola samega.
Round and yellow, engraved with "A-009" and "15" on one side.
Okrogle oblike in rumene barve z vrezano oznako “A-009” in “15” na eni strani.
• difficulty sleeping,
• sladkorna bolezen, • težave s spanjem,
- altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive
- močna želja po čezmernem hazardiranju ne glede na posledice za vas ali za družino, - spremenjeno ali povečano spolno zanimanje in vedenje, ki vam ali drugim povzroča znatno zaskrbljenost, na primer povečan libido,
Drug withdrawal syndrome neonatal (see section 4.6)
puerperija in perinatalnem obdobju sindrom odtegnitve zdravila pri novorojenčku (glejte poglavje 4.6)
In the long-term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.
V dolgotrajni 26-tedenski vzdrževalni fazi s placebom nadzorovanega preskušanja je bila pojavnost EPS pri bolnikih, ki so se zdravili z aripiprazolom 18,2 %, pri bolnikih, ki so prejemali placebo pa 15,7 %.
- uncontrollable excessive shopping
- čezmerno nakupovanje ali trošenje denarja, ki ju ne morete nadzorovati,
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively.
V kliničnem preskušanju s peroralnim aripiprazolom pri zdravih preiskovancih je močan zaviralec CYP3A4 (ketokonazol) zvečal AUC aripiprazola za 63 % in Cmax za 37 %.
How to take ABILIFY
Kako jemati zdravilo ABILIFY
Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 L/kg, indicating extensive extravascular distribution.
Porazdelitev Aripiprazol se obsežno porazdeli po telesu in ima navidezni volumen porazdelitve 4,9 l/kg, kar kaže na izdatno zunajžilno porazdelitev.
Blood glucose fluctuation Creatine phosphokinase increased
Neznana pogostnost hemoglobina nihanje vrednosti glukoze v krvi zvišana aktivnost kreatinfosfokinaze
What you need to know before you are given ABILIFY Do not use ABILIFY
Kaj morate vedeti, preden boste uporabili zdravilo ABILIFY Ne uporabljajte zdravila ABILIFY
The AUC and Cmax of dehydroaripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively.
AUC aktivnega presnovka dehidroaripiprazola se je zmanjšala za 32 %, njegova Cmax pa za 47 %.
In a long-term 26-week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients.
V dolgoročnem 26-tedenskem s placebom nadzorovanem preskušanju je bila incidenca EPS pri bolnikih, zdravljenih z aripiprazolom, 19 % in pri bolnikih, ki so dobivali placebo, 13,1 %.
Round and pink, engraved with "A-011" and "30" on one side.
Okrogle oblike in roza barve z vrezano oznako “A-011” in “30” na eni strani.
Manic episodes in Bipolar I Disorder: the recommended starting dose for ABILIFY is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1).
Manične epizode pri bipolarni motnji I: priporočeni začetni odmerek zdravila ABILIFY je 15 mg enkrat na dan ne glede na obroke hrane, in sicer kot samostojno zdravilo ali v sklopu kombiniranega zdravljenja (glejte poglavje 5.1).
Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.
Kajenje Populacijska farmakokinetična raziskava peroralnega aripiprazola ni pokazala klinično pomembnih vplivov kajenja na farmakokinetiko aripiprazola.
No dosage adjustment is required for patients with mild to moderate hepatic impairment.
Pri bolnikih z blago do zmerno okvaro jeter odmerka ni treba prilagajati.
Each vial contains 9.75 mg aripiprazole.
Ena viala vsebuje 9,75 mg aripiprazola.
Renal impairment No dosage adjustment is required in patients with renal impairment.
Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati.
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals.
Manične epizode pri bipolarni motnji I pri mladostnikih, starih 13 let in več: priporočeni odmerek zdravila ABILIFY je 10 mg enkrat na dan ne glede na obrok hrane.
Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus allergic, or urticaria)
vključno z oteklino jezika, edem jezika, edem obraza, alergijsko srbenje ali urtikarija)
In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 to 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.
V 6-tedenskem s placebom nadzorovanem preskušanju, ki je vključevalo 302 mladostnika (13 do 17 let) s shizofrenijo s pozitivnimi in negativnimi simptomi, je bil aripiprazol povezan s statistično značilno večjim izboljšanjem psihotičnih simptomov v primerjavi s placebom.
When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced.
Pri sočasni uporabi močnih zaviralcev CYP3A4 ali CYP2D6 in aripiprazola je treba odmerek aripiprazola zmanjšati.
In one short-term (24-hour) placebo-controlled trial involving 291 patients with bipolar disorder presenting with agitation and disturbed behaviours, ABILIFY solution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to the reference arm lorazepam.
291 bolnikov z bipolarno motnjo, pri katerih je bila prisotna agitacija in vedenjske motnje, je bilo zdravilo ABILIFY raztopina za injiciranje ABILIFY povezano s statistično pomembnim izboljšanjem agitacije/vedenjskih simptomov v primerjavi s placebom in primerljiv z lorazepamom.
EU/1/04/276/033 - 50 mL bottle EU/1/04/276/034 - 150 mL bottle EU/1/04/276/035 - 480 mL bottle
EU/1/04/276/033 - 50-ml plastenka EU/1/04/276/034 - 150-ml plastenka EU/1/04/276/035 - 480-ml plastenka
ABILIFY 5 mg tablets are rectangular and blue, marked with ‘A-007' and ‘5' on one side.
Tablete ABILIFY 5 mg so pravokotne in modre, označene z 'A-007' in '5' na eni strani.
Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in na škatli poleg oznake “Upor.
Talk to your doctor about the best way to feed your baby if you are receiving this medicine.
Če prejemate to zdravilo, se z zdravnikom posvetujte o najprimernejših načinih hranjenja otroka.
ABILIFY is for oral use.
Zdravilo ABILIFY je namenjeno za peroralno uporabo.
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.
Kajenje Populacijska farmakokinetična analiza ni pokazala klinično pomembnih učinkov kajenja na farmakokinetiko apiprazola.
ABILIFY 30 mg tablets are round and pink, marked with ‘A-011' and ‘30' on one side.
Tablete ABILIFY 30 mg so okrogle in roza, označene z 'A-011' in '30' na eni strani.
The administration of ABILIFY solution for injection had no effect on the pharmacokinetics of lorazepam solution for injection when administered concomitantly.
Pri sočasni uporabi zdravila ABILIFY raztopina za injiciranje ne vpliva na farmakokinetiko lorazepama v obliki raztopine za injiciranje.
Each mL contains 7.5 mg of aripiprazole.
En ml vsebuje 7,5 mg aripiprazola.
Administration of ABILIFY solution for injection was well tolerated and produced no direct target organ toxicity in rats or monkeys after repeated dosing at systemic exposures (AUC) that were 15 and 5 times, respectively, human exposure at the maximum recommended human dose of 30 mg intramuscular.
Podgane in opice so ponavljajoče se odmerke aripiprazola v obliki raztopine za injiciranje dobro prenašale (sistemska izpostavljenost (AUC) je bila pri podganah za 15-krat, pri opicah pa za 5-krat večja od izpostavljenosti človeka po največjem priporočenem intramuskularnem odmerku pri človeku (30 mg)).
In another long-term 26-week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.
V drugem dolgoročnem 26-tedenskem nadzorovanem preskušanju je bila incidenca EPS pri bolnikih, zdravljenih z aripiprazolom, 14,8 % in pri bolnikih, zdravljenih z olanzapinom, 15,1 %.
Schizophrenia: the recommended starting dose for ABILIFY is 10 mg/day or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
Shizofrenija: priporočeni začetni odmerek zdravila ABILIFY je 10 mg/dan ali 15 mg/dan, vzdrževalni odmerek pa 15 mg/dan, uporabljen enkrat na dan ne glede na obroke.
A lower dose of 5.25 mg (0.7 mL) may be given, on the basis of individual clinical status, which should also include consideration of medicinal products already administered either for maintenance or acute treatment (see section 4.5).
ABILIFY v obliki raztopine za injiciranje je pri enkratnem injiciranju učinkovit pri odmerkih v razponu od 5,25 mg do 15 mg. Na osnovi individualnega kliničnega statusa, pri čemer je treba upoštevati tudi že dana zdravila, bodisi zaradi vzdrževalnega bodisi akutnega zdravljenja (glejte poglavje 4.5), lahko bolnik prejme tudi odmerek,
This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free'.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na enoto odmerka, kar v bistvu pomeni ‘brez natrija'.
Aspartame (E 951)
indigotin (E 132)
Do not use this medicine after the expiry date which is stated on the bottle and on the carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in na škatli poleg oznake “Upor.
Each carton contains one bottle and both a calibrated polypropylene measuring cup and a calibrated polypropylene low-density polyethylene dropping pipette.
Ena škatla vsebuje 1 plastenko, umerjeno odmerno čašo iz polipropilena in umerjeno kapalko iz polipropilena in polietilena majhne gostote.
However, you should not dilute with other liquids or mix with other food prior to taking ABILIFY oral solution.
Vendar pa zdravila ABILIFY pred zaužitjem ne smete redčiti z drugimi tekočinami ali mešati s hrano.
ABILIFY tablets contain lactose.
Tablete ABILIFY vsebujejo laktozo.
The recommended dose is 9.75 mg (1.3 mL) for the first injection.
Priporočeni odmerek pri prvem injiciranju je 9,75 mg (1,3 ml).
However, in a single-dose, intramuscular study of aripiprazole (dose 15 mg) in healthy subjects, administered simultaneously with intramuscular lorazepam (dose 2 mg), the orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone.
Vendar pa je v študiji pri zdravih osebah, ki so prejele enkratni intramuskularni odmerek aripiprazola (15 mg) skupaj z enkratnim intramuskularnim odmerkom lorazepama (2 mg), bila stopnja sedacije pri uporabi kombinacije večja kot pri uporabi lorazepama samega.
ABILIFY 7.5 mg/mL solution for injection
ABILIFY 7,5 mg/ml raztopina za injiciranje
ABILIFY contains aspartame
Zdravilo ABILIFY vsebuje aspartam
Use in children and adolescents The recommended dose for adolescents is 10 mL solution (corresponding to 10 mg aripiprazole)
Uporaba pri otrocih in mladostnikih Priporočeni odmerek za mladostnike je 10 ml raztopine (kar ustreza 10 mg aripiprazola) enkrat na dan, toda vaš zdravnik vam lahko predpiše odmerek, ki je manjši ali večji, do največ 30 ml (tj.